Nyxoah S.A.·Healthcare

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 20, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 1,031,323 new shares on May 20, 2026 in connection with the contribution in kind of a receivable held by the holder of the convertible bonds issued by the Company on December 18, 2025. For more information on this transaction, please refer to the special report of the board of directors dated May 19, 20261.

Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum

Nyxoah SA (NYXH) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Nyxoah SA (NYXH) Q1 2026 Earnings Call Transcript

Nyxoah NASDAQ: NYXH reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization.

Nyxoah SA (NYXH) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.63 per share a year ago.
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Healthcare
Medical - Instruments & Supplies
183
2021-04-28
0.88